EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone

Friederike Amann iD, Gudrun Hefner, Peter Cremer-Schaeffer, Gerhard Gründer iD, Winfried Häuser, Xenia M Hart, Frank Petzke, Gerald Zernig, Ursula Havemann-Reinecke

Pharmacopsychiatry · 2026-11 · 59 (06) · 345-357

DOI: 10.1055/a-2853-4984 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacopsychiatry, online erschienen am 10.06.2026. Verfasst von Friederike Amann und 8 weiteren Autor:innen. Beteiligte Einrichtung: Central Institute of Mental Health, Department of Molecular Neuroimaging, Medical Faculty Mannheim, University of Heidelberg , Germany, Mannheim. Hauptthemen laut MEDLINE: Dronabinol, Drug Monitoring, Cannabidiol, Medical Marijuana. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medical cannabis, nabiximols, dronabinol and nabilone are used for various medical conditions. Despite their pronounced pharmacokinetic variability and complex concentration–effect relationships, therapeutic drug monitoring recommendations are lacking. We aimed to identify therapeutic reference ranges based on blood concentration–clinical effect relationships. Studies reporting blood concentrations and clinical effects/adverse effects or assessing cannabinoid receptors 1 and 2 occupancy were selected through a systematic literature search in the MEDLINE database via PubMed. Twenty-three articles were selected for vaporized/smoked medical cannabis, three for nabiximols, nine for dronabinol and one for nabilone. No article was identified for delta-9-tetrahydrocannabinol-dominant cannabis extracts. For vaporized/smoked medical cannabis, an orienting therapeutic reference range of 15–30 ng/mL delta-9-tetrahydrocannabinol was identified for pain reduction in diabetic peripheral neuropathy, while concentrations of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DronabinolDrug MonitoringCannabidiolMedical MarijuanaCannabinoidsHumansDrug CombinationsReference Values

Substanzen

DronabinolCannabidiolnabilonenabiximolsMedical MarijuanaDrug CombinationsCannabinoids

Autor:innen und Institutionen

  • Central Institute of Mental Health, Department of Molecular Neuroimaging, Medical Faculty Mannheim, University of Heidelberg , Germany, Mannheim.
  • German Center for Mental Health (DZPG)-partner site Mannheim-Heidelberg-Ulm, Germany, Mannheim.
  • Society for Neuropsychopharmacology and Pharmacopsychiatry (AGNP), Germany, Mannheim.
  • Psychiatric Hospital, Vitos Clinic for Forensic Psychiatry, Germany, Eltville.
  • Bundesopiumstelle, Bundesinstitut für Arzneimittel und Medizinprodukte, Germany, Bonn.
  • Medical Center Pain Medicine and Mental Health Saarbruecken, Germany, Saarbruecken.

ORCID-Profile: Friederike Amann, Gerhard Gründer

Zitieren

APA

Amann, F., Hefner, G., Cremer-Schaeffer, P., Gründer, G., Häuser, W., Hart, X. M., Petzke, F., Zernig, G., & Havemann-Reinecke, U. (2026). Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone. Pharmacopsychiatry, 59(06), 345-357. https://doi.org/10.1055/a-2853-4984

Vancouver

Amann F, Hefner G, Cremer-Schaeffer P, Gründer G, Häuser W, Hart XM, et al. Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone. Pharmacopsychiatry. 2026;59(06):345-357. doi:10.1055/a-2853-4984

BibTeX
@article{Amann2026,
  author = {Amann, Friederike and Hefner, Gudrun and Cremer-Schaeffer, Peter and Gründer, Gerhard and Häuser, Winfried and Hart, Xenia M and Petzke, Frank and Zernig, Gerald and Havemann-Reinecke, Ursula},
  title = {Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone},
  journal = {Pharmacopsychiatry},
  year = {2026},
  volume = {59},
  number = {06},
  pages = {345--357},
  doi = {10.1055/a-2853-4984}
}
Kostenlos starten →